Preparation of Tri-n-alkyl[P-32] phosphine Oxide for latent Treatment of Hepatic Tumors

被引:0
作者
Choi, Kang-Hyuk [1 ]
Youn, Kwan-Sik [1 ]
Yu, Kook-Hyun [1 ]
机构
[1] Dongguk Univ, Dept Chem, Seoul 100715, South Korea
来源
JOURNAL OF THE KOREAN CHEMICAL SOCIETY-DAEHAN HWAHAK HOE JEE | 2005年 / 49卷 / 02期
关键词
LUF; Oily Lymphographic Agent; Lipiodol; P-32] H3PO4; Tri-n-alkyl[P-32] Phosphine Oxide;
D O I
10.5012/jkcs.2005.49.2.161
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The element phosphorus, a component of low molecular intermediate and nucleic acid, plays an important role in metabolism in body. And so P-32 and its labeled compounds have been studied in the fields of biology, genetic engineering and so forth. However, P-32 labeling compounds have been insufficiently studied in part of treatment despite many researches on tracers. In line of application research of the [(32) P]H3PO4, we have focused on the LUF (Lipiodol Ultra-Fluid), an oily lymphographic, which have been used in hepatography and have prepared LUF alternatives( tri-n-alkyl[(32) P] phosphine oxide). Comparative materials, Tri-n-alkylphosphine Oxide, have been synthesized with Grignard reaction and yields are 17% for butyl, 29% for octyl and 52% for dodecyl. P-(32) exchange reactions take precedence of Grignard reaction for preparation of precursor [(32) P] POCl3 of tri-n-alkyl[(32) P] phosphine oxide. Exchanging yield is over 96% confirmed of Radio TLC scanner. The labeling yields of tri-n-alkyl[(32) P] phosphine oxide are 91%, 60%, and 96% respectively for butyl, octyl and dodecyl
引用
收藏
页码:161 / 166
页数:6
相关论文
共 18 条
[1]  
Anne-Dominique Fortineau, 1999, J LABELLED COMPD RAD, V42, P527
[2]   Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP [J].
Breitz, H ;
Wendt, R ;
Stabin, M ;
Bouchet, L ;
Wessels, B .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) :225-230
[3]  
Brunke Karen J, 2004, US PAT APPL PUBL, V24, P976
[4]  
Gan H N, 1978, BRIT J RADIOL, V51, P788
[5]  
Han J. G, 1992, J KOREAN SOC HOSP PH, V9, P209
[6]  
IWAI K, 1984, CANCER RES, V44, P2115
[7]  
KAN ZX, 1989, ACTA RADIOL, V30, P419
[8]  
KEENAN RW, 1982, J BIOL CHEM, V257, P4817
[9]  
NAKAKUMA K, 1983, CANCER, V52, P2193, DOI 10.1002/1097-0142(19831215)52:12<2193::AID-CNCR2820521203>3.0.CO
[10]  
2-R